We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Rejects Pfizer’s Final Offer, Says Sweetened Deal Still Undervalues Company
AstraZeneca Rejects Pfizer’s Final Offer, Says Sweetened Deal Still Undervalues Company
The AstraZeneca board of directors on Monday rejected a sweetened, final merger offer from U.S. rival Pfizer, but at least one industry analyst expects wrangling will continue, especially if AZ shareholders step up and demand that the board returns to the negotiating table.